Sponsored by
Last week, FDA granted accelerated approval for tovorafenib (brand name OjemdaTM). This is great news for pediatric low-grade glioma (pLGG) patients and families. FDA had approved another drug combo (dabrafenib with trametinib) for BRAF V600E-mutated pLGG last year, but OjemdaTM is the first approved drug for both BRAF mutations and fusions. Early research for this drug was supported by the Team Jack Foundation in Nebraska, and it was brought to market by Day One Biopharmaceuticals - congratulations to all who contributed!